@drkameshaglp1's compounded semaglutide experience, reviewed

What does this TikTok actually claim?

Dr. Kamesha shares her personal experience using compounded semaglutide, positioning herself as a "GLP-1 bestie" while promoting a compound pharmacy called KinMeds. She describes her journey with the medication but doesn't specify her starting dose, timeline, or actual weight loss numbers.

The video focuses more on her general experience rather than making specific medical claims. However, by presenting herself as both a doctor and someone successfully using the medication, she's essentially endorsing both compounded semaglutide and this particular pharmacy.

What's missing here is important context about compounded versus FDA-approved versions, potential risks, and whether her experience represents typical results.

Is compounded semaglutide the same as brand-name versions?

Not exactly, and this distinction matters more than Dr. Kamesha suggests. Compounded semaglutide isn't FDA-approved and doesn't undergo the same quality testing as Ozempic or Wegovy.

The FDA has issued multiple warnings about compounded GLP-1 medications. In March 2024, they flagged several compound pharmacies for safety violations, including incorrect dosing and contamination issues. Unlike Novo Nordisk's semaglutide, which showed 14.9% weight loss in the STEP 1 trial (Wilding et al., NEJM, 2021), compounded versions have no published efficacy data.

That doesn't mean compounded semaglutide doesn't work. The active ingredient is the same. But you're essentially getting an untested version of a tested drug, often at a fraction of the cost.

The regulatory gray area

Compound pharmacies can legally make semaglutide only when there's a documented shortage of the FDA-approved version. As of late 2024, the FDA removed semaglutide from its shortage list, technically making most compounding illegal.

Dr. Kamesha doesn't mention this regulatory complexity, which patients need to understand before choosing compounded options.

What about the KinMeds promotion?

Here's where things get problematic. Dr. Kamesha specifically mentions KinMeds, a telehealth platform that provides compounded semaglutide, without disclosing any potential financial relationship.

Medical professionals promoting specific companies, especially in weight loss spaces, should be transparent about sponsorships or affiliate relationships. The FTC requires clear disclosure of financial relationships in social media posts, something that's often ignored in health-focused TikToks.

KinMeds isn't necessarily a bad option, but patients deserve to know if their doctor is being paid to recommend it.

Does her experience represent typical results?

Impossible to say without specifics. Dr. Kamesha doesn't share her starting weight, current weight, dosage, or timeline. This makes her "experience" essentially meaningless as actionable information.

Clinical trial data shows wide variation in semaglutide response. In the STEP 1 trial, while the average was 14.9% weight loss, some participants lost over 20% while others lost less than 5%. Individual genetics, starting BMI, and lifestyle factors all influence outcomes.

Personal testimonials, even from doctors, can't replace clinical evidence. Dr. Kamesha's experience might be fantastic, but it doesn't predict what you'll experience.

What should you actually know about compounded semaglutide?

The science behind semaglutide is solid. It works by activating GLP-1 receptors, slowing gastric emptying and reducing appetite. Starting doses typically begin at 0.25mg weekly, escalating to 2.4mg for weight loss.

But choosing compounded over FDA-approved versions involves trade-offs. You'll likely save money but sacrifice quality assurance and regulatory oversight. Some patients report excellent results with compounded versions, while others experience inconsistent dosing or side effects.

If you're considering compounded semaglutide, work with a doctor who can monitor your progress and adjust dosing appropriately. Don't rely on TikTok testimonials, even from medical professionals, to make this decision.